



Press release  
20 November 2007

## **Tripep convenes an extraordinary general meeting**

The Board of Directors of Tripep AB convenes an extraordinary general meeting to take place on 19 December, 2007 at 10 am. Location: Hälsovägen 7 in Huddinge. The EGM shall resolve an amendment of the provisions of the articles of association regarding the limits of the share capital and the number of authorized shares.

The proposed amendment of the articles of association is a part of the preparations for a new issue of shares. The Board of Directors will convene a second EGM which will also take place on 19 December, 2007, immediately after the first EGM. The second EGM shall resolve the terms and conditions for the new issue. The Board of Directors intends to propose a rights issue which shall be fully guaranteed. Notice of the second EGM will be announced not later than 5 December, 2007.

### **For more information, please contact:**

**Jan Nilsson**, CEO, Tripep AB  
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63  
E-mail: [jan.nilsson@tripep.se](mailto:jan.nilsson@tripep.se)

**Anders Vahlne**, Head of Research, Tripep AB  
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28  
E-mail: [anders.vahlne@ki.se](mailto:anders.vahlne@ki.se)

*Tripep develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal and a therapeutic vaccine against Hepatitis C, named ChronVac-C<sup>®</sup>, plus the RAS<sup>®</sup> technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company's Website: [www.tripep.se](http://www.tripep.se).*